[HTML][HTML] The etiology of rheumatoid arthritis
HU Scherer, T Häupl, GR Burmester - Journal of autoimmunity, 2020 - Elsevier
Rheumatoid arthritis is a heterogeneous disease, which can be, based on data combining
genetic risk factors and autoantibodies, sub-classified into ACPA-positive and-negative RA …
genetic risk factors and autoantibodies, sub-classified into ACPA-positive and-negative RA …
[HTML][HTML] Rheumatoid arthritis: a brief overview of the treatment
Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease,
affecting the joints with varying severity among patients. The risk factors include age …
affecting the joints with varying severity among patients. The risk factors include age …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
JS Smolen, R Landewé, J Bijlsma… - Annals of the …, 2017 - ard.bmj.com
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international …
Against Rheumatism (EULAR) RA management recommendations. A large international …
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised …
Summary Background Upadacitinib, an oral Janus kinase (JAK) 1-selective inhibitor,
showed efficacy in combination with stable background conventional synthetic disease …
showed efficacy in combination with stable background conventional synthetic disease …
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of …
A Sepriano, A Kerschbaumer, JS Smolen… - Annals of the …, 2020 - ard.bmj.com
Objectives To perform a systematic literature review (SLR) concerning the safety of synthetic
(s) and biological (b) disease-modifying anti rheumatic dugs (DMARDs) to inform the 2019 …
(s) and biological (b) disease-modifying anti rheumatic dugs (DMARDs) to inform the 2019 …
2016 update of the EULAR recommendations for the management of early arthritis
Objectives Since the 2007 recommendations for the management of early arthritis have
been presented, considerable research has been published in the field of early arthritis …
been presented, considerable research has been published in the field of early arthritis …
2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases
A De Thurah, P Bosch, A Marques… - Annals of the …, 2022 - ard.bmj.com
Background Remote care and telehealth have the potential to expand healthcare access,
and the COVID-19 pandemic has called for alternative solutions to conventional face-to-face …
and the COVID-19 pandemic has called for alternative solutions to conventional face-to-face …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
JS Smolen, RBM Landewé, JWJ Bijlsma… - Annals of the …, 2020 - ard.bmj.com
Objectives To provide an update of the European League Against Rheumatism (EULAR)
rheumatoid arthritis (RA) management recommendations to account for the most recent …
rheumatoid arthritis (RA) management recommendations to account for the most recent …
Treating juvenile idiopathic arthritis to target: recommendations of an international task force
Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an
achievable goal for most patients. Reaching this target leads to improved outcomes. The …
achievable goal for most patients. Reaching this target leads to improved outcomes. The …
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis …
C Roubille, V Richer, T Starnino, C McCourt… - Annals of the …, 2015 - ard.bmj.com
The objective of this systematic literature review was to determine the association between
cardiovascular events (CVEs) and antirheumatic drugs in rheumatoid arthritis (RA) and …
cardiovascular events (CVEs) and antirheumatic drugs in rheumatoid arthritis (RA) and …